Pfizer is currently trading at Rs. 4416.75, up by 157.90 points or 3.71% from its previous closing of Rs. 4258.85 on the BSE.The scrip opened at Rs. 4274.95 and has touched a high and low of Rs. 4929.85 and Rs. 4271.15 respectively. So far 36100 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 4,929.85 on 03-Mar-2020 and a 52 week low of Rs. 2797.50 on 23-Aug-2019.Last one week high and low of the scrip stood at Rs. 4929.85 and Rs. 4054.85 respectively. The current market cap of the company is Rs. 20213.41 crore.The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 16.72% and 19.36% respectively.Pfizer’s parent company in the US has reportedly found some antiviral compounds that have the potential to inhibit coronavirus. The company is engaging with a third party to screen the compounds and it hopes that they would get the results from screening by the end of March. If any of the compounds are successful the company would start testing them by the end of the year.Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

The Revenue for the quarter ended  September 2019 of Rs. 5670.60 millions grew by 9.10 % from Rs. 5197.40 millions.Net profit for the quarter ended September 2019 increased significantly by 61.01% to Rs. 1542.50 millions from Rs. 958.00 millions.Operating profit surged to 2089.30 millions from the corresponding previous quarter of 1668.30 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201909 201809 % Var 201909 201809 % Var 201903 201803 % Var Sales 5670.60 5197.40 9.10 11114.60 10320.50 7.69 20815.00 19801.90 5.12 Other Income 447.50 370.60 20.75 805.80 675.90 19.22 1673.90 1142.90 46.46 PBIDT 2089.30 1668.30 25.24 4109.90 3274.70 25.50 7325.90 6145.80 19.20 Interest 26.20 2.20 1090.91 47.70 3.90 1123.08 12.90 4.20 207.14 PBDT 2063.10 1666.10 23.83 4062.20 3270.80 24.20 7313.00 6141.60 19.07 Depreciation 251.30 177.30 41.74 501.30 360.10 39.21 713.90 662.50 7.76 PBT 1811.80 1488.80 21.70 3560.90 2910.70 22.34 6599.10 5479.10 20.44 TAX 269.30 530.80 -49.27 890.30 1034.30 -13.92 2308.60 1878.40 22.90 Deferred Tax -62.80 -44.90 39.87 -146.90 -71.30 106.03 -129.10 -66.50 94.14 PAT 1542.50 958.00 61.01 2670.60 1876.40 42.33 4290.50 3600.70 19.16 Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00 PBIDTM(%) 36.84 32.10 14.78 36.98 31.73 16.54 35.20 31.04 13.40

A fair growth of 6.26% in the revenue at Rs. 5444.00 millions was reported in the June 2019 quarter as compared to Rs. 5123.10 millions during year-ago period.The Company has registered profit of Rs. 1128.10  millions for the quarter ended June 2019, a growth of 22.83%  over Rs. 918.40 millions millions achieved in the corresponding quarter of last year.Operating profit for the quarter ended June 2019 rose to 2020.60 millions as compared to 1606.40 millions of corresponding quarter ended June 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 5444.00 5123.10 6.26 5444.00 5123.10 6.26 20815.00 19801.90 5.12 Other Income 358.30 305.30 17.36 358.30 305.30 17.36 1673.90 1142.90 46.46 PBIDT 2020.60 1606.40 25.78 2020.60 1606.40 25.78 7325.90 6145.80 19.20 Interest 21.50 1.70 1164.71 21.50 1.70 1164.71 12.90 4.20 207.14 PBDT 1999.10 1604.70 24.58 1999.10 1604.70 24.58 7313.00 6141.60 19.07 Depreciation 250.00 182.80 36.76 250.00 182.80 36.76 713.90 662.50 7.76 PBT 1749.10 1421.90 23.01 1749.10 1421.90 23.01 6599.10 5479.10 20.44 TAX 621.00 503.50 23.34 621.00 503.50 23.34 2308.60 1878.40 22.90 Deferred Tax -84.10 -26.40 218.56 -84.10 -26.40 218.56 -129.10 -66.50 94.14 PAT 1128.10 918.40 22.83 1128.10 918.40 22.83 4290.50 3600.70 19.16 Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00 PBIDTM(%) 37.12 31.36 18.37 37.12 31.36 18.37 35.20 31.04 13.40

Pfizer is currently trading at Rs. 2796.70, up by 115.20 points or 4.30% from its previous closing of Rs. 2681.50 on the BSE.The scrip opened at Rs. 2799.00 and has touched a high and low of Rs. 2844.00 and Rs. 2781.10 respectively. So far 7419 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 3840.00 on 29-Aug-2018 and a 52 week low of Rs. 2050.60 on 23-Mar-2018.Last one week high and low of the scrip stood at Rs. 2844.00 and Rs. 2650.00 respectively. The current market cap of the company is Rs. 12800.22 crore.The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 15.98% and 20.10% respectively.The company has reported a rise of 51.24% in its net profit at Rs 131.94 crore for third quarter ended December 31, 2018 as compared to Rs 87.24 crore for the same quarter in the previous year. Total income of the company increased by 18.32% at Rs 578.14 crore for Q3FY19 as compared Rs 488.62 crore for the corresponding quarter previous year.Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer is currently trading at Rs. 2890.00, up by 11.25 points or 0.39% from its previous closing of Rs. 2878.75 on the BSE.The scrip opened at Rs. 2911.35 and has touched a high and low of Rs. 2958.00 and Rs. 2883.40 respectively. So far 1881 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 3840.00 on 29-Aug-2018 and a 52 week low of Rs. 1999.00 on 27-Dec-2017.Last one week high and low of the scrip stood at Rs. 2958.00 and Rs. 2817.00 respectively. The current market cap of the company is Rs. 13204.17 crore.The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 15.60% and 20.48% respectively.Pfizer’s parent company -- Pfizer Inc., USA, and GlaxoSmithKline pie have entered into an agreement to create a premier global consumer healthcare company. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business.Pfizer Inc. USA that the portfolio of this Joint Venture Company will not include the brands Corex, Gelusil and Becosules. These brands will continue to be marketed by Pfizer in India.Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer is currently trading at Rs. 2865.00, up by 86.25 points or 3.10% from its previous closing of Rs. 2778.75 on the BSE.The scrip opened at Rs. 2815.50 and has touched a high and low of Rs. 2866.80 and Rs. 2808.00 respectively. So far 418 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 3840.00 on 29-Aug-2018 and a 52 week low of Rs. 1865.00 on 29-Nov-2017.Last one week high and low of the scrip stood at Rs. 2,893.20 and Rs. 2755.00 respectively. The current market cap of the company is Rs. 12877.99 crore.The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 15.60% and 20.48% respectively.Pfizer has reported 13.81% fall in its net profit at Rs 95.80 crore for the quarter ended September 30, 2018 as compared to Rs 111.15 crore for the same quarter in the previous year. Total income of the company decreased by 6.39% at Rs 556.80 crore for Q2FY19 as compared Rs 594.82 crore for the corresponding quarter previous year.Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Net sales declined -8.99%  to  Rs. 5197.40 million from Rs. 5711.10 millions.Net profit declined -13.81% to Rs. 958.00 millions from Rs. 1111.50 millions.Operating Profit reported a sharp decline to 1668.30 millions from 1909.50 millions in the corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201803 201703 % Var Sales 5197.40 5711.10 -8.99 10320.50 10037.00 2.82 19801.90 20419.30 -3.02 Other Income 370.60 237.10 56.31 675.90 509.80 32.58 1142.90 1011.60 12.98 PBIDT 1668.30 1909.50 -12.63 3274.70 2948.80 11.05 6145.80 4502.90 36.49 Interest 2.20 1.60 37.50 3.90 3.40 14.71 4.20 9.60 -56.25 PBDT 1666.10 1907.90 -12.67 3270.80 2945.40 11.05 6141.60 5797.60 5.93 Depreciation 177.30 160.20 10.67 360.10 312.50 15.23 662.50 629.30 5.28 PBT 1488.80 1747.70 -14.81 2910.70 2632.90 10.55 5479.10 5168.30 6.01 TAX 530.80 636.20 -16.57 1034.30 949.70 8.91 1878.40 1800.50 4.33 Deferred Tax -44.90 -106.00 -57.64 -71.30 -124.50 -42.73 -66.50 -86.10 -22.76 PAT 958.00 1111.50 -13.81 1876.40 1683.20 11.48 3600.70 3367.80 6.92 Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00 PBIDTM(%) 32.10 33.43 -4.00 31.73 29.38 8.00 31.04 22.05 40.74

The revenue for the June 2018 quarter is pegged at Rs. 5123.10 millions, about 18.43% up against Rs. 4325.90 millions recorded during the year-ago period.Net profit surges 60.64% to Rs. 918.40  millions  from Rs. 571.70 millions in the quarter ended June 2018.Operating profit for the quarter ended June 2018 rose to 1606.40 millions as compared to 1039.30 millions of corresponding quarter ended June 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 5123.10 4325.90 18.43 5123.10 4325.90 18.43 19801.90 20419.30 -3.02 Other Income 305.30 272.70 11.95 305.30 272.70 11.95 1142.90 1011.60 12.98 PBIDT 1606.40 1039.30 54.57 1606.40 1039.30 54.57 6145.80 4502.90 36.49 Interest 1.70 1.80 -5.56 1.70 1.80 -5.56 4.20 9.60 -56.25 PBDT 1604.70 1037.50 54.67 1604.70 1037.50 54.67 6141.60 5797.60 5.93 Depreciation 182.80 152.30 20.03 182.80 152.30 20.03 662.50 629.30 5.28 PBT 1421.90 885.20 60.63 1421.90 885.20 60.63 5479.10 5168.30 6.01 TAX 503.50 313.50 60.61 503.50 313.50 60.61 1878.40 1800.50 4.33 Deferred Tax -26.40 -18.50 42.70 -26.40 -18.50 42.70 -66.50 -86.10 -22.76 PAT 918.40 571.70 60.64 918.40 571.70 60.64 3600.70 3367.80 6.92 Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00 PBIDTM(%) 31.36 24.03 30.51 31.36 24.03 30.51 31.04 22.05 40.74

Pfizer scrip is currently trading at Rs. 2583.10, up by 49.00 points or 1.93% from its previous closing of Rs. 2534.10 on the BSE.The scrip opened at Rs. 2530.00 and has touched a high and low of Rs. 2597.05 and Rs. 2525.00 respectively. So far 359 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 2670.00 on 20-Jun-2018 and a 52 week low of Rs. 1701.00 on 12-Oct-2017.Last one week high and low of the scrip stood at Rs. 2,597.05 and Rs. 2505.00 respectively. The current market cap of the company is Rs. 11825.79 crore.The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 14.92% and 21.16% respectively.Pfizer is reportedly planning to split its business into three units and one of them would include a new hospital business segment. The three new units of the company will be established medicines, consumer healthcare and innovative medicines. The innovative medicines business and consumer healthcare would together comprise about three-quarter of its revenue based on 2017 results.The company’s new business structure represents a natural evolution, ongoing strength in-market products and late-stage pipeline and the expected significant reduction in the impact of patent protection losses post-2020.Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer is currently trading at Rs. 2426.00, down by 75.40 points or 3.01% from its previous closing of Rs. 2501.40 on the BSE.The scrip opened at Rs. 2540.00 and has touched a high and low of Rs. 2550.00 and Rs. 2402.65 respectively. So far 7634 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 2,550.00 on 08-May-2018 and a 52 week low of Rs. 1625.00 on 08-Jun-2017.Last one week high and low of the scrip stood at Rs. 2,550.00 and Rs. 2230.00 respectively. The current market cap of the company is Rs. 11084.68 crore.The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 14.92% and 21.16% respectively.The company has reported a rise of 53.60% in its net profit at Rs 104.51 crore for the quarter ended March 31, 2018 as compared to Rs 68.04 crore for the same quarter in the previous year. Total income of the company has increased by 14.36% at Rs 551.18 crore for quarter under review as compared to Rs 481.97 crore for the quarter ended March 31, 2017.For the year ended March 31, 2018, the company has posted a rise of 6.92% in its net profit at Rs 360.07 crore as compared to Rs 336.78 crore for the same period in the previous year. However, total income of company decreased marginally 2.27% at Rs 2,094.48 crore for year under review as compared to Rs 2,143.09 crore for the period ended March 31, 2017.

Net sales declined -10.52%  to  Rs. 4565.40 million from Rs. 5102.30 millions.Net Profit recorded in the quarter ended December 2017 rise to 39.87% to Rs. 872.40  millions  compared to R. 623.70 millions in corresponding previous quarter.Operating profit surged to 1500.10 millions from the corresponding previous quarter of 886.80 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 4565.40 5102.30 -10.52 14602.40 15887.60 -8.09 20419.30 20937.60 -2.48 Other Income 320.80 265.20 20.97 830.60 723.60 14.79 1011.60 869.90 16.29 PBIDT 1500.10 886.80 69.16 4448.90 3268.40 36.12 4502.90 5189.90 -13.24 Interest 2.00 2.30 -13.04 5.40 8.30 -34.94 9.60 5.20 84.62 PBDT 1498.10 1074.90 39.37 4443.50 4564.40 -2.65 5797.60 5283.60 9.73 Depreciation 177.30 154.10 15.06 489.80 464.80 5.38 629.30 579.30 8.63 PBT 1320.80 920.80 43.44 3953.70 4099.60 -3.56 5168.30 4704.30 9.86 TAX 448.40 297.10 50.93 1398.10 1412.20 -1.00 1800.50 1654.40 8.83 Deferred Tax -34.80 -80.60 -56.82 -159.30 -170.20 -6.40 -86.10 -223.70 -61.51 PAT 872.40 623.70 39.87 2555.60 2687.40 -4.90 3367.80 3049.90 10.42 Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00 PBIDTM(%) 32.86 17.38 89.05 30.47 20.57 48.10 22.05 24.79 -11.03

With no major difference for the quarter endedSeptember 2017 , the total revenue stood at Rs. 5711.10  millions.Net profit declined -12.02% to Rs. 1111.50 millions from Rs. 1263.30 millions.Operating profit for the quarter ended September 2017 rose to 1909.50 millions as compared to 1155.10 millions of corresponding quarter ended September 2016. (Rs. in Million) Quarter ended Year to Date Year ended 201709 201609 % Var 201709 201609 % Var 201703 201603 % Var Sales 5711.10 5576.60 2.41 10037.00 10785.30 -6.94 20419.30 20937.60 -2.48 Other Income 237.10 243.00 -2.43 509.80 458.40 11.21 1011.60 869.90 16.29 PBIDT 1909.50 1155.10 65.31 2948.80 2381.60 23.82 4502.90 5189.90 -13.24 Interest 1.60 1.80 -11.11 3.40 6.00 -43.33 9.60 5.20 84.62 PBDT 1907.90 2187.90 -12.80 2945.40 3489.50 -15.59 5797.60 5283.60 9.73 Depreciation 160.20 160.90 -0.44 312.50 310.70 0.58 629.30 579.30 8.63 PBT 1747.70 2027.00 -13.78 2632.90 3178.80 -17.17 5168.30 4704.30 9.86 TAX 636.20 763.70 -16.70 949.70 1115.10 -14.83 1800.50 1654.40 8.83 Deferred Tax -106.00 -59.40 78.45 -124.50 -89.60 38.95 -86.10 -223.70 -61.51 PAT 1111.50 1263.30 -12.02 1683.20 2063.70 -18.44 3367.80 3049.90 10.42 Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00 PBIDTM(%) 33.43 20.71 61.42 29.38 22.08 33.05 22.05 24.79 -11.03